Lanvis

Lanvis Use In Pregnancy & Lactation

tioguanine

Manufacturer:

Aspen

Distributor:

Zuellig Pharma
Full Prescribing Info
Use In Pregnancy & Lactation
LANVIS like other cytotoxic agents is potentially teratogenic.
There have been isolated cases where men who have received combinations of cytotoxic agents including LANVIS, have fathered children with congenital abnormalities.
The use of LANVIS should be avoided whenever possible during pregnancy, particularly during the first trimester. In any individual case the potential hazard to the foetus must be balanced against the expected benefit to the mother.
As with all cytotoxic chemotherapy, adequate contraceptive precautions should be advised when either partner is receiving LANVIS.
There are no reports documenting the presence of thioguanine or its metabolites in maternal milk. It is suggested that mothers receiving LANVIS should not breast feed.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in